{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-24-006945","form_type":"8-K","ticker":"EDSA","cik":"0001540159","company_name":"Edesa Biotech, Inc.","filed_at":"2024-12-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.746293+00:00","generated_at":"2026-05-29T03:35:22.645888+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Edesa Biotech FY2024 net loss $6.2M ($1.93/sh); cash $1.0M, negative working capital","bullets":["Net loss $6.2M ($1.93/sh) vs $8.4M ($2.93/sh) prior year; operating expenses down 24% to $7.0M.","Cash and equivalents $1.0M at Sep 30; negative working capital of $0.2M.","Post-year end: $1.5M from CEO-affiliated entity + $0.6M net from ATM offering.","Pivoted EB05 (paridiprubart) to U.S. govt-funded ARDS study; plans EB06 IND submission.","Topline Phase 2 EB06 results expected 12-18 months after FDA clearance; funded subject to capital."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-24-006945","json":"https://secwatch.observer/filing/0001171843-24-006945.json","markdown":"https://secwatch.observer/filing/0001171843-24-006945.md","text":"https://secwatch.observer/filing/0001171843-24-006945.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1540159/000117184324006945/0001171843-24-006945-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1540159/000117184324006945/f8k_121324.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T03:35:22.645888+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}